Medical Billing · Nationwide
Addiction Medicine & SUD Medical Billing Services
Opioid Treatment Program (OTP) weekly bundles, Office-Based Opioid Treatment (OBOT) buprenorphine induction, per diem residential billing, and definitive urine toxicology.
Aethera Healthcare Solutions provides full-service medical billing and revenue cycle management to addiction medicine clinics, OTP programs, and residential treatment centers across the United States. We handle coding, claims, payment posting, denial management, and A/R follow-up end to end — so your team can stay focused on patient care while your revenue cycle runs cleanly.
Typical addiction medicine & sud CPT range we work: G2086–G2088, G2074–G2080, H0001, H0004, H0015, H0020, H0035, G0480–G0483.
Why addiction medicine & sud billing leaks revenue
Medicare OTP weekly bundle denials: G2074–G2080 bundled claims rejected when dispensing dates or counseling minutes do not match MAC billing schedules
Office-Based Opioid Treatment (OBOT) induction under-reimbursement: Failing to capture initial month intensive assessment and induction add-ons (G2086)
Definitive drug testing clawbacks: Commercial payers recouping multi-drug class UDT (G0480–G0483) panels when lacking individualized clinical justification
Parity Act non-compliance: Commercial payers arbitrarily capping residential bed days below ASAM criteria recommendations
How Aethera fixes it
Specialty-trained coders (CPC/CCS) code to the documentation
First-pass claim scrubbing against payer and NCCI edits
Proactive denial prevention and 72-hour denial work
Relentless A/R follow-up to drive days-in-A/R down
Eligibility and prior-auth verification before service
Transparent, real-time reporting in the provider portal
Free tools for your billing team
Use these any time — no login required.
Addiction Medicine & SUD billing FAQ
How do you bill Medicare Opioid Treatment Program (OTP) weekly bundled codes?
We bill HCPCS G2074–G2080 corresponding to the specific medication (methadone, buprenorphine, or naltrexone) with paired dispensing and clinical counseling documentation meeting CMS Chapter 17 requirements.
How do you prevent urine drug screen denials in addiction treatment?
We separate presumptive point-of-care screening (80305) from physician-ordered definitive mass spectrometry confirmation (G0480), attaching specific clinical reasoning and risk level documentation for each test.